BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27750236)

  • 1. Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Ida H; Sakurai T; Kitano M; Nishida N; Kudo M
    Dig Dis; 2016; 34(6):671-678. PubMed ID: 27750236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Kitano M; Nishida N; Kudo M
    Oncology; 2015; 89 Suppl 2():47-52. PubMed ID: 26584036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):583-588. PubMed ID: 29040991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Kim JH; Shim JH; Lee HC; Sung KB; Ko HK; Ko GY; Gwon DI; Kim JW; Lim YS; Park SH
    Liver Int; 2017 Dec; 37(12):1861-1868. PubMed ID: 28581250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).
    Kudo M; Arizumi T; Ueshima K; Sakurai T; Kitano M; Nishida N
    Dig Dis; 2015 Oct; 33(6):751-8. PubMed ID: 26488473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
    Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
    Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma.
    Wang JH; Kee KM; Lin CY; Hung CH; Chen CH; Lee CM; Lu SN
    J Gastroenterol Hepatol; 2015 Feb; 30(2):358-63. PubMed ID: 25088668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
    Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
    Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis.
    Ha Y; Shim JH; Kim SO; Kim KM; Lim YS; Lee HC
    J Gastroenterol Hepatol; 2014 Apr; 29(4):787-93. PubMed ID: 24224567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification.
    Yamamoto M; Kobayashi T; Hashimoto M; Kuroda S; Kawaoka T; Aikata H; Chayama K; Ohdan H
    BMC Cancer; 2021 Jun; 21(1):668. PubMed ID: 34090354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
    Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
    Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.
    Longo L; Rodrigues de Freitas LB; Santos D; Grivicich I; Álvares-da-Silva MR
    Am J Clin Oncol; 2019 May; 42(5):466-471. PubMed ID: 30913090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients.
    Zhaohui Z; Shunli S; Bin C; Shaoqiang L; Yunpeng H; Ming K; Lijian L; Gang PB
    Cancer Res Treat; 2019 Jan; 51(1):65-72. PubMed ID: 29510616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
    Jun CH; Yoon JH; Cho E; Shin SS; Cho SB; Kim HJ; Park CH; Kim HS; Choi SK; Rew JS
    Medicine (Baltimore); 2017 Apr; 96(17):e6745. PubMed ID: 28445298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients.
    Weinmann A; Koch S; Sprinzl M; Kloeckner R; Schulze-Bergkamen H; Düber C; Lang H; Otto G; Wörns MA; Galle PR
    Liver Int; 2015 Feb; 35(2):591-600. PubMed ID: 25290314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Itobayashi E; Nouso K; Kariyama K; Ishikawa T; Hirooka M; Hiasa Y
    Cancer Sci; 2017 Jul; 108(7):1414-1420. PubMed ID: 28406546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group.
    Farinati F; Vanin V; Giacomin A; Pozzan C; Cillo U; Vitale A; Di Nolfo AM; Del Poggio P; Benvegnu' L; Rapaccini G; Zoli M; Borzio F; Giannini EG; Caturelli E; Trevisani F;
    Liver Int; 2015 Jan; 35(1):223-31. PubMed ID: 25074434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.